English
Back
Download
Log in to access Online Inquiry
Back to the Top

UPDATES

$Immutep (IMMP.US)$ Immutep Reports Initial Safety Data For IMP761, The First LAG-3 Agonist, In Phase I Trial With No Treatment-Related Adverse Events; Additional Data Expected In H1 2025 To Support Autoimmune Disease Treatment Potential
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
Translate
Report
742 Views
Comment
Sign in to post a comment
    198
    Followers
    38
    Following
    841
    Visitors
    Follow
    Reassessing Chinese Assets
    Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.